Verteporfin

Suppliers

Names

[ Name ]:
Verteporfin

[Synonym ]:
trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid 3,4,9-trimethyl ester
Visudyne
,3(28),4,6,8,10,12,14,16(26),17,19,21-dodécaén-9-yl]propanoïque - acide 3-[(1Z,6Z,12Z,17Z,23S,24R)-14-éthényl-22,23-bis(méthoxycarbonyl)-9-(3-méthoxy-3-oxopropyl)-4,10,15,24-tétraméthyl-25,26,27,28-té
VERTEPORFIN (200 MG)
trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropionic Acid Monomethyl Ester
,4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic acid - 3-[(1Z,6Z,12Z,17Z,23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahex
,4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propansäure--3-[(1Z,6Z,12Z,17Z,23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyc
Verteporphin
3-[(1Z,6Z,12Z,17Z,23S,24R)-22,23-Bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-14-vinyl-25,26,27,28-tetraazahexacyclo[16.6.1.1.1.1.0]octacosa-1,3(28),4 ,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic acid - 3-[(1Z,6Z,12Z,17Z,23S,24R)-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-14-vinyl-25,26,27,28-tetraazahexacyc lo[16.6.1.1.1.1.0]o
Verteprofin

Chemical & Physical Properties

[ Molecular Formula ]:
C₄₁H₄₂N₄O₈

[ Molecular Weight ]:
718.79

[ PSA ]:
337.48000

[ LogP ]:
10.24600

[ Storage condition ]:
?20°C

[ Water Solubility ]:
DMSO: soluble2mg/mL, clear (warmed)

MSDS

Click to get detail MSDS

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration.

Eur. J. Ophthalmol. 16(6) , 824-34, (2006)

Choroidal neovascularization associated with age-related macular degeneration is the primary cause of blindness in the elderly in developed countries, due to a number of pathogenic effects, including ...

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Cancer Discov. 5 , 1178-93, (2015)

Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, is implicated in this interact...

Aerobic glycolysis tunes YAP/TAZ transcriptional activity.

EMBO J. 34 , 1349-70, (2015)

Increased glucose metabolism and reprogramming toward aerobic glycolysis are a hallmark of cancer cells, meeting their metabolic needs for sustained cell proliferation. Metabolic reprogramming is usua...